Registration Number
0219U003158,
0118U003430
, R & D reports
Title
To improve laboratory monitoring of hemophilia patients treatment on the basis of studying the mechanisms of action of blood clotting preparations using a complex of coagulogic and global tests of hemostasis
popup.stage_title
Head
Stasyshyn Oleksandra Vasylivna, д.мед.н.
Registration Date
24-01-2019
Organization
State Institution Institute of Blood Pathology and Transfusion Medicine of National Academy of Medicfl Sciences of Ukraine
popup.description2
Object of the study: 19 severe hemophilia A patients in the age from 1,5 to 60 years old who were examined and treated at the SI "Institute of Blood Pathology and Transfusion Medicine of the UNAMS" (Lviv). Objective: to develop parameters of laboratory monitoring of hemostatic therapy with the aim of optimization and individualization of treatment of hemophilia patients on the basis of studying the mechanisms of action of hemostic agents. Clinical and laboratory studies included clinical, cytological, hematological, biochemical, general coagulation and thromboelastogram (TEG). We used the hematological analyzer Micros 60 No. 814773, the Pentra-400 biochemical analyzer, No. 807P4-2012, the Helena-C4 semi-automatic coagulometer, No. C4-2561, TEG 5000® Haemoscope Corp., Niles IL, No. S091204020. In patients with hemophilia A in the recovery test (RT) before injection, there was a violation of APTT, IAPTT, the level of FVIII and antigen FVIII are decreased. We found a violation in the direction of the hypocoagulation of TEG results indicators characterizing coagulation hemostasis was, and which was normalized after the introduction of the FVIII concentrate. During prophylaxis, correlations of TEG indices with the indicators of traditional hemostasis tests, which reflect similar processes of соagulation, have been established. TEG can be a reliable global test for the evaluation of the results obtained in RT, control of the appearance of inhibitors and treatment of hemophilia patients. In previously treated hemophilia A patients, when switching to prophylactic treatment or "on demand" treatment with modified recombinant drugs, neutralizing inhibitors of FVIII (IX) do not develope. In the case of prophylaxis, the annual bleeding rating is reduced, the spontaneous bleeding and joint hemorrhage is reduced. It has been found that modified FVIII (IX) recombinant concentrates have a prolonged half-life, which reduces the frequency of their administration, maintaining a factor activity more than 1.0%.
Product Description
popup.authors
Дзісь Р.П.
Красівська В.В.
Семерак М.М.
Тушницький О.М.
popup.nrat_date
2020-04-02
